Eli Lilly (LLY) and Amgen (AMGN) filed a complaint Friday against the US Department of Health and Human Services, alleging that the agency unlawfully certified and recertified clinics that treat sexually transmitted diseases to participate in a federal drug discount program.
The plaintiffs said in the lawsuit that the court "should set aside the agency's unlawful certifications and recertifications of these ineligible entities and enjoin the agency from certifying or recertifying these entities in the future."
The Department of Health and Human Services did not immediately reply to a request for comment from MT Newswires.
Price: 791.19, Change: +23.43, Percent Change: +3.05
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。